• Brian Fengler, MD — Co-Founder & CMO, EvidenceCare
    Nov 16 2026

    Brian Fengler, an emergency physician and co-founder and chief medical officer of EvidenceCare, joins Steve Labkoff and Leon Rozenblit to talk about getting evidence and performance data to doctors while they can still use it. He tells the story of the patient who started the company, explains why one metric a week, shown next to colleagues' results, changes how physicians practice, and describes how a CEO's bed-status problem reshaped the business. Then Steve asks the hard one: when the numbers improve, how do you know it was you? They close on data rights, governance, and what to ask an AI-enabled vendor.

    Show More Show Less
    53 mins
  • John Halamka, MD, MS: What Big Data Can and Can't Answer
    Nov 8 2026

    John Halamka, president of Mayo Clinic Platform, joins Steve Labkoff and Leon Rozenblit to ask what large health datasets can answer and where they run out. A registry will record a patient's toenail length; a medical record won't. John makes the case for testing ideas in real-world data before spending on a trial, and Leon presses him on where randomization still has to happen. They also get into governing thousands of AI skills, why Steve hears an echo of MYCIN, and why John thinks people trust large language models too much.

    Show More Show Less
    56 mins
  • Adam Blum Returns: One Record Instead of Many Extracts
    Nov 1 2026

    Adam Blum returns to talk about what sits underneath his clinical-trial matcher: PRomop, an open-source patient record built on OMOP. Now CTO of HealthKey.ai, which acquired CancerBot this year, Adam argues that organizations can replace their transactional, analytics, and decision-ready stores with one, and that a single flat record per disease is enough. Leon Rozenblit pushes back on whether one record can serve many questions, and Steve Labkoff presses on staleness and where the AI actually lives. Steve advises HealthKey and co-authored the PRomop paper with Adam.

    Show More Show Less
    49 mins
  • Charles (Charlie) Safran, MD, MS: 50 Years of AI in Medicine
    Oct 25 2026

    In 1973, Charlie Safran wrote programs for an MIT group that expected a computer doctor by the year 2000. Fifty years later, the former chief of clinical informatics at Beth Israel Deaconess and past AMIA chair walks Steve Labkoff and Leon Rozenblit through what changed and what didn't: Bayesian decision models for Hodgkin's disease, rules of care in early electronic health records, why those rules were so hard to maintain, and why clinical data will always reflect what gets paid for. His conclusion: reasoning turned out to be the easier part, and technology should make care more human, not less.

    Show More Show Less
    54 mins
  • Reflections #9: Where Healthcare AI Actually Is
    Oct 18 2026

    Six conversations into Season 2, Steve Labkoff and Leon Rozenblit look back at what they added up to. They revisit Raihan Faroqui on AI agents at the front desk, Greg Raiz on data over gut feel in pre-seed investing, Randi Seigel and Jared Augenstein on the state-by-state map of AI law, Travis Zack on an evidence engine that grades its own sources, Sir Peter Donnelly on genetics as nature's drug trial, and Latha Valluripalli Soorya and Erica Crawford on smart glasses in the autism evaluation. Their read: the field is moving from hype into implementation, efficiency keeps arriving before accuracy, and "AI" may be too broad a word to regulate or even to argue about.

    Show More Show Less
    56 mins
  • Latha Valluripalli Soorya & Erica Crawford: Smart Glasses in Autism Evaluation
    Oct 11 2026

    Families who suspect autism can wait up to two years for an evaluation. Dr. Latha Valluripalli Soorya, a clinical psychologist at Rush University Medical Center and co-founder of Argus Cognitive, and Dr. Erica Crawford, Clinical Director at Autism Testing 4 Kids in Dallas–Fort Worth, join Steve Labkoff and Leon Rozenblit to discuss Neurora: smart glasses a clinician wears during a standard autism assessment, with software that measures a child's gaze, facial movement and speech. AT4K was a reimbursed site in its FDA study. They cover what the clinician gets back, the hard cases where the data helps, what the published study does and doesn't show, and why the biggest time savings so far came from report writing.

    Show More Show Less
    51 mins
  • Sir Peter Donnelly of Genomics: Genetics as Nature's Drug Trial
    Oct 4 2026

    Ninety-five percent of drug targets fail, and Professor Sir Peter Donnelly thinks the reason is simple: we can't run experiments on humans. Genetics is the next best thing. People who carry natural variants in a gene show what happens when that gene is dialed up or down over a lifetime. Peter, CEO and co-founder of Genomics, joins Steve Labkoff and Leon Rozenblit to explain how his company harmonized tens of thousands of genetic studies into one resource, what genetics revealed about "good" cholesterol, why the AI agent sits on top rather than at the core, and what genetics still can't tell a drug developer.

    Show More Show Less
    55 mins
  • Travis Zack: How OpenEvidence Picks and Grades the Evidence
    Sep 27 2026

    Doctors hallucinate too. That's the provocation Travis Zack, MD, PhD, chief medical officer of OpenEvidence, brings to this conversation with Steve Labkoff and Leon Rozenblit. A physician with 20 patients and no time to look things up goes with their gut, and can get it wrong in the same ways a language model does. Travis explains why OpenEvidence was built on retrieving evidence rather than generating answers, what makes one set of references better than another, how it grades the strength of evidence behind an answer in real time, why health systems and EHR vendors act as gatekeepers, and why the last mile of a clinical decision still belongs to a human.

    Show More Show Less
    55 mins